Ropidoxuridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ropidoxuridine
DrugBank Accession Number
DB06485
Background

Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 338.101
Monoisotopic: 337.97635
Chemical Formula
C9H11IN2O4
Synonyms
  • Ropidoxuridine
External IDs
  • NSC-726188

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Pyrimidine nucleosides
Sub Class
Pyrimidine 2'-deoxyribonucleosides
Direct Parent
Pyrimidine 2'-deoxyribonucleosides
Alternative Parents
Pyrimidones / Halopyrimidines / Hydropyrimidines / Aryl iodides / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds / Primary alcohols
show 5 more
Substituents
Alcohol / Aromatic heteromonocyclic compound / Aryl halide / Aryl iodide / Azacycle / Halopyrimidine / Heteroaromatic compound / Hydrocarbon derivative / Hydropyrimidine / Organic nitrogen compound
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
3HX21A3SQF
CAS number
93265-81-7
InChI Key
XIJXHOVKJAXCGJ-XLPZGREQSA-N
InChI
InChI=1S/C9H11IN2O4/c10-5-2-11-9(15)12(3-5)8-1-6(14)7(4-13)16-8/h2-3,6-8,13-14H,1,4H2/t6-,7+,8+/m0/s1
IUPAC Name
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2-dihydropyrimidin-2-one
SMILES
OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C=NC1=O

References

General References
Not Available
ChemSpider
8016494
ChEMBL
CHEMBL2103821
ZINC
ZINC000006091380

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Bile Duct Carcinoma / Stage II Esophageal Cancer AJCC v7 / Stage II Pancreatic Cancer AJCC v6 and v7 / Stage IIA Esophageal Cancer AJCC v7 / Stage IIA Pancreatic Cancer AJCC v6 and v7 / Stage IIB Esophageal Cancer AJCC v7 / Stage IIB Pancreatic Cancer AJCC v6 and v7 / Stage III Colon Cancer AJCC v7 / Stage III Esophageal Cancer AJCC v7 / Stage III Gastric Cancer AJCC v7 / Stage III Liver Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage III Rectal Cancer AJCC v7 / Stage III Small Intestinal Cancer AJCC v7 / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Esophageal Cancer AJCC v7 / Stage IIIA Gastric Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIA Small Intestinal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Esophageal Cancer AJCC v7 / Stage IIIB Gastric Cancer AJCC v7 / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIB Small Intestinal Cancer AJCC v7 / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Esophageal Cancer AJCC v7 / Stage IIIC Gastric Cancer AJCC v7 / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Esophageal Cancer AJCC v7 / Stage IV Gastric Cancer AJCC v7 / Stage IV Liver Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IV Rectal Cancer AJCC v7 / Stage IV Small Intestinal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / Stage IVA Liver Cancer / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Stage IVB Liver Cancer / Stage IVB Rectal Cancer AJCC v71
1RecruitingTreatmentHematopoietic and Lymphoid Cell Neoplasm / Malignant Solid Neoplasm / Metastatic Malignant Neoplasm in the Brain1
1RecruitingTreatmentLocally Advanced Rectal Carcinoma / Rectal Adenocarcinoma / Stage II Rectal Cancer AJCC v8 / Stage IIA Rectal Cancer AJCC v8 / Stage IIB Rectal Cancer AJCC v8 / Stage IIC Rectal Cancer AJCC v8 / Stage III Rectal Cancer AJCC v8 / Stage IIIA Rectal Cancer AJCC v8 / Stage IIIB Rectal Cancer AJCC v8 / Stage IIIC Rectal Cancer AJCC v81

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.13 mg/mLALOGPS
logP-0.63ALOGPS
logP-0.32ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity63.51 m3·mol-1ChemAxon
Polarizability25.32 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on March 19, 2008 16:34 / Updated on February 21, 2021 18:52